Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, March 29, 2024 · 699,672,739 Articles · 3+ Million Readers

Kaposi Sarcoma Market to reach a value of US$143.2 mn by 2024, Says TMR

Key Players in Global Kaposi Sarcoma Market to Focus on Technological Advancements to Encourage Growth

Albany, NY, Aug. 14, 2018 (GLOBE NEWSWIRE) -- According to the market intelligence study by Transparency Market Research, the global Kaposi sarcoma market was worth US$118.5 mn in 2015 and is anticipated to reach a value of US$143.2 mn by the end of 2024. The market is predicted to register a steady 2.20% CAGR between 2016 and 2024.

Presence of Leading Players to Drive North America Kaposi Sarcoma Market

The global market for Kaposi sarcoma has been categorized on the basis of geography into Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa. Among these, North America led the global market in the last few years and is likely to remain in the similar position in the coming few years. The presence of a large number of leading players and the increasing costs of drugs are some of the major factors that are estimated to enhance the growth of the North America market in the next few years. In addition to this, the easy availability of advanced drugs and the technologically advanced healthcare are some of the other factors that are predicted to enhance the growth of the market in the near future. Furthermore, the Middle East and Africa is estimated to witness a healthy growth in the near future.

Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354

The global Kaposi sarcoma market has been categorized on the basis of treatments into chemotherapy, immunotherapy, and antiretroviral therapy. Among these, the antiretroviral therapy segment is expected to account for a major share of the overall market in the next few years. The rising incidence rate of AIDS-associated Kaposi sarcoma is one of the key factors predicted to enhance the growth of the market in the coming few years. Furthermore, the rising preference for this treatment and the high cost of treatment are some of the other factors that are predicted to enhance the growth of this segment in the next few years.

Request PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3354

Rising Cases of Cancer to Encourage Growth of Kaposi Sarcoma Market

The increasing procedures for organ transplants and the rising incidence of cancer are the key factors that are projected to encourage the growth of the global Kaposi sarcoma market in the next few years. Furthermore, the rising cases of HIV/AIDS related to Kaposi sarcoma is another key factor, which is likely to accelerate the growth of the overall market in the next few years. In addition to this, the technological advancements in the healthcare sector and the introduction of new drugs for Kaposi sarcoma are projected to enhance the growth of the Kaposi sarcoma market in the next few years.

Request for Discount on This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=3354

The global market for Kaposi sarcoma is highly consolidated in nature with two players holding a massive share of the market, states a new market intelligence study that’s has been recently published by Transparency Market Research. In 2015, the two leading players, namely Merck & Co. Inc. and Johnson & Johnson held a share of around 50% of the global market and is projected to remain in the similar situation in the next few years. The rising research and development activities in this field and the technological advancements are some of the major factors that are anticipated to enhance the growth of the global Kaposi sarcoma market in the coming few years. In addition to this, the increasing mergers and acquisitions and strategic collaboration is further anticipated to accelerate the growth of the overall market in the next few years.

Read Press Release: https://www.transparencymarketresearch.com/pressrelease/kaposis-sarcoma-market.htm

This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Kaposi Sarcoma Market (Treatment – Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel – Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

More Trending Reports by Transparency Market Research -

Allergy Immunotherapy Market: https://www.transparencymarketresearch.com/allergy-immunotherapy-market.html

Cancer Immunotherapy Market: https://www.transparencymarketresearch.com/cancer-immunotherapy-market.html

Key Takeaways:

  • The rising incidence of cancer is one of the key factors encouraging the growth of the Kaposi sarcoma market in the next few years.
  • The rising level of competition and the increasing focus on development of new products are predicted to enhance the growth of the market in the near future.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact 

Mr. Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Research Blog: http://theglobalhealthnews.com/

Primary Logo

Powered by EIN News
Distribution channels:


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release